New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries

PAPERBACK
$43.50

Download

Table of Contents
Front Matter R1-R16
1. Summary 1-18
2. Priority Setting for Health-Related Investments: A Review of Methods 19-29
3. Overview of the Analytic Approach 30-43
4. Comparison of Disease Burdens 44-62
5. Predictions of Vaccine Development 63-75
6. Assessing the Likely Utilization of New Vaccines 76-81
7. Calculation and Comparison of the Health Benefits and Differential Costs Associated with Candidate Vaccines 82-105
8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development 106-120
9. Findings, Conclusions, and Recommendations 121-142
Appendix A: Selection of Vaccine Candidates for Accelerated Development 143-148
Appendix B: The Burden of Disease Resulting from Acute Respiratory Illness 149-158
Appendix C: The Burden of Disease Resulting from Diarrhea 159-169
Appendix D-1: The Prospects for Immunizing Against Dengue Virus 170-177
Appendix D-2: The Prospects for Immunizing Against Escherichia coli 178-185
Appendix D-3: The Prospects for Immunizing Against Hemophilus influenzae Type b 186-196
Appendix D-4: The Prospects for Immunizing Against Hepatitis A Virus 197-207
Appendix D-5: The Prospects for Immunizing Against Hepatitis B Virus 208-222
Appendix D-6: The Prospects for Immunizing Against Japanese Encephalitis Virus 223-240
Appendix D-7: The Prospects for Immunizing Against Mycobacterium leprae 241-250
Appendix D-8: The Prospects for Immunizing Against Neisseria meningitidis 251-266
Appendix D-9: The Prospects for Immunizing Against Parainfluenza Viruses 267-274
Appendix D-10: The Prospects for Immunizing Against Plasmodium spp. 275-286
Appendix D-11: The Prospects for Immunizing Against Rabies Virus 287-298
Appendix D-12: The Prospects for Immunizing Against Respiratory Syncytial Virus 299-307
Appendix D-13: The Prospects for Immunizing Against Rotavirus 308-318
Appendix D-14: The Prospects for Immunizing Against Salmonella typhi 319-328
Appendix D-15: The Prospects for Immunizing Against Shigella spp. 329-337
Appendix D-16: The Prospects for Immunizing Against Streptococcus Group A 338-356
Appendix D-17: The Prospects for Immunizing Against Streptococcus pneumoniae 357-375
Appendix D-18: The Prospects for Immunizing Against Vibrio cholerae 376-389
Appendix D-19: The Prospects for Immunizing Against Yellow Fever 390-402
Appendix E: Questionnaire for Assessing Morbidity-Mortality Trade-Offs 403-411
Appendix F: Technical Notes 412-412
Appendix G: Biographical Notes on Committee Members 413-417
Appendix H: Additional Sources of Advice to the Committee 418-419
Appendix I: Contents of Supplement to Volume II 420-420
Appendix J: Preface to Volume I 421-422
Appendix K: Contents to Volume I 423-423
Index 424-432

EXAMPLE 6: Here, infant deaths are worse than deaths in the elderly. Ten deaths in the elderly are equal to the death of one infant.

Please be sure to fill out the entire tables. All answers will be regarded as strictly confidential.

Table of Contents

Front Matter R1-R16

1. Summary 1-18

2. Priority Setting for Health-Related Investments: A Review of Methods 19-29

3. Overview of the Analytic Approach 30-43

4. Comparison of Disease Burdens 44-62

5. Predictions of Vaccine Development 63-75

6. Assessing the Likely Utilization of New Vaccines 76-81

7. Calculation and Comparison of the Health Benefits and Differential Costs Associated with Candidate Vaccines 82-105

8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development 106-120

9. Findings, Conclusions, and Recommendations 121-142

Appendix A: Selection of Vaccine Candidates for Accelerated Development 143-148

Appendix B: The Burden of Disease Resulting from Acute Respiratory Illness 149-158

Appendix C: The Burden of Disease Resulting from Diarrhea 159-169

Appendix D-1: The Prospects for Immunizing Against Dengue Virus 170-177

Appendix D-2: The Prospects for Immunizing Against Escherichia coli 178-185

Appendix D-3: The Prospects for Immunizing Against Hemophilus influenzae Type b 186-196

Appendix D-4: The Prospects for Immunizing Against Hepatitis A Virus 197-207

Appendix D-5: The Prospects for Immunizing Against Hepatitis B Virus 208-222

Appendix D-6: The Prospects for Immunizing Against Japanese Encephalitis Virus 223-240

Appendix D-7: The Prospects for Immunizing Against Mycobacterium leprae 241-250

Appendix D-8: The Prospects for Immunizing Against Neisseria meningitidis 251-266

Appendix D-9: The Prospects for Immunizing Against Parainfluenza Viruses 267-274

Appendix D-10: The Prospects for Immunizing Against Plasmodium spp. 275-286

Appendix D-11: The Prospects for Immunizing Against Rabies Virus 287-298

Appendix D-12: The Prospects for Immunizing Against Respiratory Syncytial Virus 299-307

Appendix D-13: The Prospects for Immunizing Against Rotavirus 308-318

Appendix D-14: The Prospects for Immunizing Against Salmonella typhi 319-328

Appendix D-15: The Prospects for Immunizing Against Shigella spp. 329-337

Appendix D-16: The Prospects for Immunizing Against Streptococcus Group A 338-356

Appendix D-17: The Prospects for Immunizing Against Streptococcus pneumoniae 357-375

Appendix D-18: The Prospects for Immunizing Against Vibrio cholerae 376-389

Appendix D-19: The Prospects for Immunizing Against Yellow Fever 390-402

Appendix E: Questionnaire for Assessing Morbidity-Mortality Trade-Offs 403-411

Appendix F: Technical Notes 412-412

Appendix G: Biographical Notes on Committee Members 413-417

Appendix H: Additional Sources of Advice to the Committee 418-419

Appendix I: Contents of Supplement to Volume II 420-420

Appendix J: Preface to Volume I 421-422

Appendix K: Contents to Volume I 423-423

Index 424-432